Biofrontera Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	34.07	28.67	24.1	18.85	26.18
Revenue Growth (YoY)	18.82%	18.98%	27.86%	-28.01%	-
Cost of Revenue	17.44	15.19	12.74	9.07	12.41
Gross Profit	16.63	13.49	11.36	9.78	13.77
Selling, General & Admin	39.13	35.87	36.51	18.12	28.7
Research & Development	0.08	0	0.7	0	0
Other Operating Expenses	0	0	0.75	1.13	3.53
Operating Expenses	39.2	35.87	37.96	19.25	32.23
Operating Income	-22.58	-22.38	-26.6	-9.47	-18.45
Interest Expense / Income	0.47	0.2	0.34	2.87	2.13
Other Expense / Income	-2.93	-21.97	10.71	-1.41	-9.64
Pretax Income	-20.12	-0.61	-37.66	-10.92	-10.95
Income Tax	0.01	0.03	0.06	0.06	0.03
Net Income	-20.13	-0.64	-37.71	-10.99	-10.98
Shares Outstanding (Basic)	2	1	0	0	0
Shares Outstanding (Diluted)	2	1	0	0	0
Shares Change	46.29%	140.00%	38330.37%	2192.00%	-
EPS (Basic)	-13.02	-0.61	-85.63	-9589.60	-219639.80
EPS (Diluted)	-13.02	-0.61	-85.63	-9589.60	-219639.80
Free Cash Flow	-24.9	-16.24	-26.73	-12.37	-38.22
Free Cash Flow Per Share	-16.10	-15.36	-60.68	-10795.55	-764300.00
Gross Margin	48.80%	47.04%	47.13%	51.90%	52.61%
Operating Margin	-66.26%	-78.05%	-110.39%	-50.22%	-70.48%
Profit Margin	-59.09%	-2.23%	-156.49%	-58.29%	-41.95%
Free Cash Flow Margin	-73.08%	-56.63%	-110.90%	-65.62%	-145.96%
EBITDA	-18.59	0.76	-36.77	-7.49	-8.15
EBITDA Margin	-54.55%	2.65%	-152.59%	-39.75%	-31.12%
Depreciation & Amortization	1.06	1.17	0.54	0.56	0.67
EBIT	-19.65	-0.41	-37.31	-8.05	-8.82
EBIT Margin	-57.67%	-1.44%	-154.83%	-42.73%	-33.67%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).